Abstract
Hypoparathyroidism is a rare endocrine disorder which leads to hypocalcemia, hypercalciuria, and hyperphosphatemia. Complications include nephrocalcinosis with renal dysfunction, reduced quality of life, and abnormal skeletal properties. Conventional therapy with calcium and vitamin D analogs addresses hypocalcemia but has important limitations. Parathyroid hormone (PTH) therapy is a fundamental advance, although the effects of PTH on long-term complications require additional testing. Continuous PTH therapy is likely to be particularly advantageous for addressing renal, quality of life, and skeletal complications. Overall, much progress has been made, yet more information is needed to improve our understanding and management of hypoparathyroidism.
Highlights
Hypoparathyroidism is a rare endocrine disorder in which the production of parathyroid hormone (PTH) by the parathyroid gland is absent or inappropriately low[1,2]
Autoimmunity targeting the parathyroid gland and, rarely, genetic disorders can lead to hypoparathyroidism[1,5]
In the pivotal REPLACE study, a 24-week, double-blind, placebocontrolled, randomized phase III study conducted with 134 patients, 53% of patients receiving rhPTH(1-84) versus 2% of patients receiving placebo met the primary study end point (≥50% reduction in calcium and calcitriol doses with maintenance of normal serum calcium)[28]
Summary
Faculty Reviews are review articles written by the prestigious Members of Faculty Opinions. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations. Any comments on the article can be found at the end of the article
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
